Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company focused on developing drugs for severe metabolic and oncologic disorders. The company is known for its work on cortisol modulation therapies. In the competitive landscape, Corcept faces rivals like Teva Pharmaceuticals and Mylan, which also focus on similar therapeutic areas.
On January 22, 2026, analyst Swayampakula Ramakanth from H.C. Wainwright set a new price target of $105 for CORT. At the time, the stock was trading at $41.47. This new target suggests a potential increase of approximately 46.8% from the current price. The price target was raised from a previous target of $90, as highlighted by TheFly.
Corcept's stock has seen a significant increase, with trading volume reaching over 3 million shares. This surge follows successful results from the company's ROSELLA Phase 3 trial. The trial tested relacorilant and nab-paclitaxel in treating platinum-resistant ovarian cancer, showing a 35% reduction in the risk of death for patients receiving the combination therapy.
The median overall survival for patients treated with relacorilant was 16 months, compared to 11.9 months for those on nab-paclitaxel alone, marking an improvement of 4.1 months. The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy. This positive outcome has likely contributed to the stock's recent performance.
Currently, CORT is priced at $41.61, reflecting a significant increase of 14.60% with a change of $5.30. During the day, the stock fluctuated between a low of $40.46 and a high of $43.50. Over the past year, CORT has reached a high of $117.33 and a low of $32.99. The company's market capitalization stands at approximately $4.38 billion, with today's trading volume at 4,189,821 shares on the NASDAQ exchange.
